Global Cell Therapy Market - Companies to Action, 2018
|発行||Frost & Sullivan||商品コード||808221|
|出版日||ページ情報||英文 88 Pages
|細胞治療の世界市場：主要企業と取り組み (2018年) Global Cell Therapy Market - Companies to Action, 2018|
|出版日: 2019年03月11日||ページ情報: 英文 88 Pages||
A Collaborative Business Model With Focus on Stem Cells, Chimeric Antigen Receptor T (CAR-T) Cells and Combination Therapies Will Propel Market Growth
The global pharmaceutical industry is continuously evolving. with the rising need for novel therapies in the ever-changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as continuously growing number of cancer cases, market needs are shifting from traditional, small molecules to novel, large-molecule therapies, with cell therapies dominating the space. The study on the "Global Cell Therapy Market, 2018, Companies to Action” presents an overview of the global cell therapy landscape, with an emphasis on the key game-changing companies disrupting this market. The study highlights the emerging companies across regions that support the development and manufacturing of novel cell therapies.
With the changing market landscape, big pharma and biopharma participants, are looking toward the adoption of a collaborative business approach by either entering into co-development and/or co-commercialization agreements or acquiring smaller, niche participants so as to achieve a competitive advantage with respect to a specific therapy area or technology. The study also delves into some of the leading strategies adopted by market participants in order to succeed in this highly dynamic market. In addition to the above-mentioned strategic analysis, information such as risk sharing and fast to market business models of some of the emerging business models across the cell therapy market is also provided.
This study identifies some of the strategies adopted by these game-changing companies with respect to key market-growth opportunities such as the use of combination therapies, manufacturing advancement and automation, adoption of newer gene-editing technologies such as CRISPR/Cas9, and so on. The study also highlights some collaborations and partnerships between these disruptive participants and throws some light on their upcoming drug pipeline; thereby, highlighting their contribution to this market. Additionally, it gives an insight into the leading strategic imperatives shaping the global industry and its long-term implication on market growth.